Abstract
Molecular radiotherapy is the use of systemically administered radiopharmaceuticals for the treatment of cancer. Molecular radiotherapy in children is most commonly indicated for thyroid cancer, neuroblastoma and other neuroendocrine tumours. The treatments most often administered are 131I-sodium iodide, 131 I-meta-iodobenzylguanidin and radiolabelled peptides such as 177Lu-Lutetium DOTATATE.
Safe administration of molecular radiotherapy to children poses special challenges and so should only be given in recognised centres. These combine radiation-protected treatment facilities in a paediatric environment with parental accommodation; medical, nursing and play specialist expertise in the care of children and the management of paediatric malignancy; and a well-equipped nuclear medicine department with medical, radiographic and physics staff experienced in diagnostic imaging, therapy administration, post-therapy imaging and dosimetry and specialist paediatric general anaesthesia available if required for optimal imaging. This may mean treatment a long way from home, and a clinical coordinator is key for communication with families and referring clinicians. Radiation protection is important, and to reduce radiation exposure to staff, parents or other suitable adults will act as comforters and cares for the child during the inpatient stay.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio TM, O’Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816
Bodey RK, Flux GD, Evans PM (2003) Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 18:89–97
British Institute of Radiology Molecular Radiotherapy Working Party (2011) BIR Report 23: molecular radiotherapy in the UK: current status and recommendations for further investigation. British Institute of Radiology, London. ISBN13: 978-0-905749-70-9
Darrouzet E, Lindenthal S, Marcellin D, Pellequer JL, Pourcher T (1838) The sodium/iodide symporter: state of the art of its molecular characterization. Biochim Biophys Acta 2014:244–253, Epub 2013 Aug 27
Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O’Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A (2014) Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas 43:518–525
Department of Health and Department of Education and Skills (2004) National service framework for children, young people and maternity services. Department of Health, London
DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, Courtier J, Mosse YP, Matthay KK (2015) Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer 17;112(4):644–649. doi:10.1038/bjc.2015.12. Epub 2015 Jan 20
Gains JE, Bomanji JB, Fersht NL, Sullivan T, D’Souza D, Sullivan KP, Aldridge M, Waddington W, Gaze MN (2011) 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 52:1041–1047, Epub 2011 Jun 16
Gains J, Mandeville H, Cork N, Brock P, Gaze M (2012) Ten challenges in the management of neuroblastoma. Future Oncol 8:839–858
Gains JE, Walker C, Sullivan TM, Waddington WA, Fersht NL, Sullivan KP, Armstrong E, D’Souza DP, Aldridge MD, Bomanji JB, Gaze MN (2014) Radiation exposure to comforters and carers during paediatric molecular radiotherapy. Pediatr Blood Cancer doi:10.1002/pbc.25250. [Epub ahead of print]
Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST (2005) Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20:195–199
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35:1039–1047
Gow MD, Seymour CB, Boyd M, Mairs RJ, Prestiwch WV, Mothersill CE (2013) Dose calculations for [(131)I] meta-iodobenzylguanidine-induced bystander effects. Dose Response 12:1–23
Health Protection Agency. Application of the 2007 recommendations of the ICRP to the UK. Advice from the Health Protection Agency. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1246519364845
Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15:1397–1406, Epub 2014 Oct 17
International Commission on Radiological Protection (2007) The 2007 recommendations of the international commission on radiological protection. ICRP Publication 103. Ann ICRP 37:2–4
Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR (2010) 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and phaeochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 95:2596–2606
Jones DH, Goldman A, Gordon I, Pritchard J, Gregory BJ, Kemshead JT (1985) Therapeutic application of a radiolabelled monoclonal antibody in nude mice xenografted with human neuroblastoma: tumoricidal effects and distribution studies. Int J Cancer 35:715–720
Kosmin MA, Bomanji JB, Cork NJ, Shankar A, Gaze MN (2012) Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma. Eur J Nucl Med Mol Imaging 39:597–601, Epub 2012 Jan 4
Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK (2007) Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 25:5465–5470
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A (2012) Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 366:1674–1685
Marincek N, Jörg AC, Brunner P, Schindler C, Koller MT, Rochlitz C, Müller-Brand J, Maecke HR, Briel M, Walter MA (2013) Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med 11:17
Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM (2009) Iodine-131-Metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approached to neuroblastoma therapy Phase I study. J Clin Oncol 27:1020–1025
Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J (2012) Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med 53:1155–1163, Epub 2012 Jun 14
Mawad R, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Shields AT, Sandmaier BM, Sorror ML, Deeg HJ, Storb R, Green DJ, Maloney DG, Appelbaum FR, Press OW, Pagel JM (2014) Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant 20:1363–1368, Epub 2014 May 20
Menda Y, O’Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O’Dorisio T, Bushnell D, Madsen M (2010) Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 51:1524–1531, Epub 2010 Sep 16
Monsieurs M, Thierens H, Dierckx RA, Casier K, De Baere E, De Ridder L, De Saedeleer C, De Winter H, Lippens M, van Imschoot S, Wulfrank D, Simons M (1998) Real life radiation burden to relatives of patients treated with Iodine-131: a study in eight centres in Flanders (Belgium). Eur J Nucl Med 25:1368–1376
National Cancer Intelligence Network (2012) National Registry of Childhood Tumours: Progress Report. www.ncin.org.uk
National Institute for Health and Clinical Excellence (2005) Improving outcomes in children and young people with cancer. National Institute for Health and Clinical Excellence, London. ISBN 1-84629-067-8
O'Donoghue JA, Bardiès M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902–1909
O’Donoghue JA (1999) Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 40:1337–1341
Perros P, Colley S, Boelaert K, Evans C, Evans RM, Gerrard GE, Gilbert JA, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold KL, Taylor J, Thakker RV, Watkinson J, Williams GR (2014) British Thyroid Association guidelines for the management of thyroid cancer, 3rd ed, Clin Endocrinol 81(Suppl 1)
Royal College of Radiologists, Society and College of Radiographers, Children’s Cancer and Leukaemia Group (2012) Good practice guide for paediatric radiotherapy. The Royal College of Radiologists, London. pp. 1–122. ISBN: 978-1-905034-59-8
Spoudeas H (ed) (2005) Paediatric endocrine tumours: a multi-disciplinary consensus statement of best practice from a working group convened under the auspices of the BSPED and UKCCSG (rare tumour working groups). The United Kingdom Children’s Cancer Study Group and British Society of Paediatric Endocrinology & Diabetes, Leicester. ISBN 0-9551487-0-7
Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, Lassmann M, Flux G (2014) The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging 41:1976–1988, Epub 2014 Jun 11
Tristam M (2001) Radiation protection. In: Fleming JS, Perkins AC (eds) Targeted radiotherapy: IPEM report 83. Institute of Physics and Engineering in Medicine, London
Vaidyanathan G, Friedman HS, Keir ST, Zalutsky MR (1996) Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nucl Med Biol 23:851–856
van der Steen J, Maessen HJ, Hoefnagel CA, Marcuse HR (1986) Radiation protection during treatment of children with 131I-meta-iodobenzylguanidine. Health Phys 50:515–522
Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN (2014) A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 50(4):801–815. doi:10.1016/j.ejca.2013.11.016. Epub 2013 Dec 12
Wong T, Matthay KK, Boscardin WJ, Hawkins RA, Brakeman PR, DuBois SG (2013) Acute changes in blood pressure in patients with neuroblastoma treated with 131I-metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer 60:1424–1430, Epub 2013 Apr 23
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children’s Oncology Group (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324–1334
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Gaze, M.N., Gains, J.E., Bomanji, J.B. (2016). Current Issues in Molecular Radiotherapy in Children. In: Mansi, L., Lopci, E., Cuccurullo, V., Chiti, A. (eds) Clinical Nuclear Medicine in Pediatrics. Springer, Cham. https://doi.org/10.1007/978-3-319-21371-2_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-21371-2_3
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21370-5
Online ISBN: 978-3-319-21371-2
eBook Packages: MedicineMedicine (R0)